Despite these advances, challenges remain due to NF-κB’s dual roles in tumor promotion and inhibition, emphasizing the need for precise targeting and careful clinical evaluation to maximize therapeutic benefits while minimizing adverse effects [62]. Here, NFKB1 is linked to neoplasm.